FDA Allows Broader Indications For Oncology Companion Dx’s
Executive Summary
New guidance from the US agency discusses how manufacturers can pursue broader indications for oncology companion diagnostics. The move could make it easier for clinicians to find the best treatment for each patient.
You may also be interested in...
Cancer IVDs Could See Label Expansions Under New Guidance
US FDA is proposing to allow cancer IVD-makers to label their tests for certain types of cancers and their therapies instead of limiting them to specific drugs and biologics. The agency says the expanded labeling is crucial to giving patients more options and help target treatments.
News We're Watching – 27 January
This feature compiles news briefs on a range of US regulatory and legal happenings. This week: Medtronic seeks HeartWare batteries; companies sign health equity pledge; insulin dosing app cleared; recall on field decontamination kits; and the renewal of an FDA panel.
Product Liability Missteps Top List Of Worst Legal Verdicts Of 2022
A recent webinar ranking last year’s best and worst legal verdicts said that product liability cases involving pelvic mesh and artificial lenses were the very worst.